drugset / Trial / NCT04702841
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
Phase 0
Unknown
8 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant tumors.The main purpose of this study was to evaluate the efficacy of car - γ δ T cell infusion in patients with relapsed and refractory CD7 Positive T cell-derived malignancies.
Timeline
- Start
- 2020-06-03
- Primary completion
- 2022-06
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chimeric antigen receptor modified γδ T cells | Cell therapy | 0.2 cells/kg | Intravenous |
| Subject | Chimeric antigen receptor modified γδ T cells | Cell therapy | 5 cells/kg | Intravenous |